The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals (Patent Application No. 19/191,246) ...

Detailed price information for Pmgc Holdings Inc (ELAB-Q) from The Globe and Mail including charting and trades.

Signal Hound–manufacturer of accessible, versatile, precision test equipment–announced the release of the VNA400 to its ...

Allegro MicroSystems, Inc. ( NASDAQ: ALGM) Q4 2025 Earnings Call May 8, 2025 8:30 AM ET Jalene Hoover - Investor Relations Mike Duke - President and Chief Executive Officer Derek D’Antilio - Chief ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Provides ReciBioPharm's customers with access to NewBiologix's Xcell-Eng-HEK293 cell lines for advanced therapies <l ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsCarrie Gillard - Director, IRHarley Finkelstein ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

In 2017, the World Health Organization (WHO) endorsed the first ITN capable of improving protection against ...